RT Journal Article
SR Electronic
T1 High-throughput fetal-fraction amplification increases analytical performance of noninvasive prenatal screening
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.12.20034926
DO 10.1101/2020.07.12.20034926
A1 Welker, Noah C.
A1 Lee, Albert K.
A1 Kjolby, Rachel A.S.
A1 Wan, Helen Y.
A1 Theilmann, Mark R.
A1 Jeon, Diana
A1 Goldberg, James D.
A1 Haas, Kevin R.
A1 Muzzey, Dale
A1 Chu, Clement S.
YR 2020
UL http://medrxiv.org/content/early/2020/07/20/2020.07.12.20034926.abstract
AB Purpose The percentage of a maternal cell-free DNA (cfDNA) sample that is fetal-derived (the fetal fraction; FF) is a key driver of the sensitivity and specificity of noninvasive prenatal screening (NIPS). On certain NIPS platforms, >20% of women with high body-mass index (and >5% overall) receive a test failure due to low FF (<4%).Methods A scalable fetal-fraction amplification (FFA) technology was analytically validated on 1,264 samples undergoing whole-genome sequencing (WGS)-based NIPS. All samples were tested with and without FFA.Results Zero samples had FF<4% when screened with FFA, whereas 1 in 25 of these same patients had FF<4% without FFA. The average increase in FF was 3.9-fold for samples with low FF (2.3-fold overall) and 99.8% had higher FF with FFA. For all abnormalities screened on NIPS, z-scores increased 2.2-fold on average in positive samples and remained unchanged in negative samples, powering an increase in NIPS sensitivity and specificity.Conclusions FFA transforms low-FF samples into high-FF samples. By combining FFA with WGS-based NIPS, a single round of NIPS can provide nearly all women with confident results about the broad range of potential fetal chromosomal abnormalities across the genome.Competing Interest StatementAll authors are current or former employees and equity holders of Myriad Genetics.Funding StatementNo external funding supported this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCertain data are available upon reasonable request to the corresponding author.